Patents by Inventor Oliver HOMANN

Oliver HOMANN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RNAI CONSTRUCTS FOR INHIBITING HSD17B13 EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20230279399
    Abstract: The present invention relates to RNAi constructs for reducing expression of the HSD17B13 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: June 3, 2021
    Publication date: September 7, 2023
    Applicant: Amgen Inc.
    Inventors: Daniel C. H. LIN, Michael OLLMANN, Justin K. MURRAY, Bradley J. HERBERICH, Amrita DAS, Patrick COLLINS, Oliver HOMANN
  • RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
    Patent number: 11732266
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: August 22, 2023
    Assignee: AMGEN INC.
    Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul, Yuan Cheng
  • RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
    Publication number: 20230078200
    Abstract: The present invention relates to RNAi constructs for reducing expression of the LPA gene, which encodes apolipoprotein(a), a component of lipoprotein(a) (Lp(a)) particles. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease, peripheral artery disease, stroke, and myocardial infarction, and to reduce serum Lp(a) levels are also described.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 16, 2023
    Applicant: AMGEN INC.
    Inventors: Bin WU, Michael OLLMANN, Oliver HOMANN, Yuan CHENG
  • RNAI CONSTRUCTS FOR INHIBITING SLC30A8 EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20220340911
    Abstract: The present invention relates to RNAi constructs for reducing expression of the SLC30A8 gene. Methods of using such RNAi constructs to treat or prevent disease, such as pre-diabetes or diabetes are also described.
    Type: Application
    Filed: August 13, 2020
    Publication date: October 27, 2022
    Applicant: AMGEN INC.
    Inventors: Wei GU, Essa Hu HARRINGTON, Oliver HOMANN
  • RNAI CONSTRUCTS FOR INHIBITING SCAP EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20220307022
    Abstract: The present invention relates to RNAi constructs for reducing expression of the SCAP gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: June 1, 2020
    Publication date: September 29, 2022
    Applicant: AMGEN INC.
    Inventors: Amrita DAS, Bradley J. HERBERICH, Justin K. MURRAY, Oliver HOMANN, Michael OLLMANN, Daniel C.H. LIN
  • RNAi CONSTRUCTS AND METHODS FOR INHIBITING MARC1 EXPRESSION
    Publication number: 20220047621
    Abstract: The present invention relates to RNAi constructs for reducing expression of the MARC1 gene. Methods of using such RNAi constructs to treat or prevent liver fibrosis and fatty liver diseases, such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, are also described.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 17, 2022
    Applicant: AMGEN INC.
    Inventors: Justin K. MURRAY, Jun ZHANG, Oliver HOMANN, Jason C. LONG, Bryan MEADE
  • RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20220017906
    Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: December 10, 2019
    Publication date: January 20, 2022
    Applicant: Amgen Inc.
    Inventors: Ingrid RULIFSON, Justin K. MURRAY, Michael OLLMANN, Oliver HOMANN
  • RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF
    Publication number: 20210139912
    Abstract: The present invention relates to RNAi constructs for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, nonalcoholic fatty liver disease (NAFLD) are also described.
    Type: Application
    Filed: December 12, 2018
    Publication date: May 13, 2021
    Applicant: AMGEN INC.
    Inventors: Ingrid RULIFSON, Justin K. MURRAY, Michael OLLMANN, Oliver HOMANN
  • RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof
    Publication number: 20210108212
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Application
    Filed: October 26, 2020
    Publication date: April 15, 2021
    Applicant: AMGEN INC.
    Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG
  • RNAi constructs for inhibiting ASGR1 expression and methods of use thereof
    Patent number: 10870856
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: December 22, 2020
    Assignee: AMGEN INC.
    Inventors: Michael Ollmann, Yang Li, Jun Zhang, Oliver Homann, Leslie P. Miranda, Justin K. Murray, Bin Wu, Oh Kyu Yoon, John Gordon Allen, Chawita Netirojjanakul
  • RNAi Constructs for Inhibiting ASGR1 Expression and Methods of Use Thereof
    Publication number: 20190309306
    Abstract: The present invention relates to RNAi constructs for reducing expression of the ASGR1 gene. Methods of using such RNAi constructs to treat or prevent cardiovascular disease, such as coronary artery disease and myocardial infarction, and to reduce serum non-HDL cholesterol levels are also described.
    Type: Application
    Filed: August 25, 2017
    Publication date: October 10, 2019
    Applicant: AMGEN INC.
    Inventors: Michael OLLMANN, Yang LI, Jun ZHANG, Kaustav BISWAS, Oliver HOMANN, Leslie P. MIRANDA, Justin K. MURRAY, Bin WU, Oh Kyu YOON, John Gordon ALLEN, Chawita NETIROJJANAKUL, Yuan CHENG